C
CALENDULA
Other Common Name: | Marigold |
Botanical Name: | Calendula officinalis |
Family: | Compositae |
Plant Part Used: | Flower |
PRESCRIBING INFORMATION
Actions | Vulnerary, antiinflammatory, lymphatic, styptic (hemostatic), antimicrobial, antiviral (topically), antifungal (topically) | |
Potential Indications |
Based on appropriate evaluation of the patient, practitioners should consider prescribing Calendula in formulations in the context of:
• Internal treatment for gastric and duodenal ulcers; enlarged or inflamed lymph nodes, acne, sebaceous cysts (5)
• Topical treatment for inflammation of the skin and mucosa, wounds, especially poorly healing wounds (4,5)
|
* This dose range is extrapolated from the British Pharmaceutical Codex 1934, the British Herbal Pharmacopoeia 1983, and the author’s education and experience.
SUPPORTING INFORMATION
1 Scientific Committee of the European Scientific Cooperative on Phytotherapy (ESCOP). ESCOP monographs: Calendulae flos. Argyle House, Gandy Street, Exeter, Devon, EX4 3LS, United Kingdom: European Scientific Cooperative on Phytotherapy, ESCOP Secretariat, March 1996.
2 Wrangsjo K, Ros AM, Wahlberg JE. Contact Dermatitis. 1990;22(3):148-154.
3 Hausen BM, Oestmann G. Derm Beruf Umwelt. 1988;36(4):117-124.
4 Goldman II. Klin Med. 1974;52(4):142-143.
5 British Herbal Medicine Association’s Scientific Committee. British herbal pharmacopoeia. Bournemouth: BHMA, 1983.
6 Felter HW, Lloyd JU. King’s American dispensatory, ed 18. Portland: Eclectic Medical Publications, 1905. rev 3, reprinted 1983.
7 Isaac I. Die Ringelblume: Botanik, Chemie, Pharmakologie, Toxikologie, Pharmazie und therapeutische Verwendung; Handbuch für ärzte, apotheker und andere naturwissenschaftler. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1992.
8 Amirghofran Z, Azadbakht M, Karimi MH. J Ethnopharmacol. 2000;72(1-2):167-172.
9 Varljen J, Liptak A, Wagner H. Phytochem. 1989;28(9):2379-2383.
10 Bezakova L, et al. Pharmazie. 1996;51:126-127.
11 Shipochliev T, Dimitrov A, Aleksandrova E. Vet Med Nauki. 1981;18(6):87-94.
12 Mascolo N, et al. Phytother Res. 1987;1:28-31.
13 Della Loggia R. Z Phytother. 2000;21:149-150.
14 Della Loggia R, et al. Planta Med. 1994;60(6):516-520.
15 Patrick KFM, et al. Phytomed. 1996;3(1):11-18.
16 Klouchek-Popova E, et al. Acta Physiol Pharmacol Bulg. 1982;8(4):63-67.
17 Ansari MA, et al. Indian Vet J. 1997;74(7):594-597.
18 Rao SG, et al. Fitoterapia. 1991;62(6):508-510.
19 Russo M. Riv Ital EPPOS. 1972;54:730.
20 Yatsuno AI, Belova LF, Lipkina GS. Pharmacol Toxicol SSSR. 1978;41:193-198.
21 Iatsyno AI, et al. Farmakol Toksikol. 1978;41(5):556-560.
22 Manolov P, et al. Probl Vatr Med. 1983;11:70-74.
23 Ahmad S, et al. Pak J Sci Ind Res. 2000;43(1):50-54.
24 Wojcicki J, Samochowiec L. Herba Pol. 1980;26:233-237.
25 Boucaud-Maitre Y, Algernon O, Raynaud J. Pharmazie. 1988;43:220-221.
26 Chakurski I, et al. Vutr Boles. 1981;20(6):51-54.
27 Fleischner AM. Cosmet Toiletries. 1985;100:54-55.
28 Garg S, Sharma SN. Pharmazie. 1992;47(12):924-926.
29 Gasiorowska I, et al. Czas Stomatol. 1983;36(4):307-311.
30 van der Velden EM, van der Dussen MFN. J Oral Maxillofac Surg. 1995;53(1):9-12.
31 Baranov AP. Dtsch Apoth Ztg. 1999;139:61-66.
32 Lievre M, et al. Clin Trials Meta-Analys. 1992;28:9-12.
33 Corina P, et al. Oftalmologia. 1999;46(1):55-57.
34 Blumenthal M, et al, editors. The complete German Commission E monographs: therapeutic guide to herbal medicines. Austin: American Botanical Council, 1998.
CALIFORNIA POPPY
Other Common Name: | Californian poppy |
Botanical Names: | Eschscholzia californica, Eschscholtzia californica# |
Family: | Papaveraceae |
Plant Part Used: | Aerial parts |
PRESCRIBING INFORMATION
Actions | Anxiolytic, mild sedative, analgesic, hypnotic | |
Potential Indications |
Based on appropriate evaluation of the patient, practitioners should consider prescribing California poppy in formulations in the context of:
|
* This dose range is extrapolated from traditional Western herbal medicine and the author’s education and experience.1
SUPPORTING INFORMATION
Traditional Prescribing | |
Native Americans and native Hispanics used the aerial parts, leaves, or flowers of California poppy for sedative and analgesic activity, to promote sleep, and for relief of toothache, particularly in children.4 | |
California poppy was of interest to medical practitioners of the United States in the late nineteenth century, with the liquid extract entered into the Park-Davis catalog in 1890. California poppy was referred to in 1892 as an “excellent soporific (sleep inducing) and analgesic, above all harmless” and in 1893, reporting that,“…the effect produced by Eschscholtzia californica upon patients is the same as that of morphine, without the inconveniences of the latter drug.”5 | |
Pharmacologic Research |
The aerial parts of California poppy contain isoquinoline alkaloids (mainly eschscholtzine and californidine, with smaller amounts of sanguinarine and chelerythrine)6 and flavonol glycosides.7
• California poppy extract inhibits the enzymatic degradation of catecholamines and the synthesis of epinephrine (adrenaline) in vitro. Preserving high levels of catecholamines may explain the sedative and antidepressant activity of California poppy.8 An extract formula containing 80% California poppy and 20% Corydalis cava has demonstrated the ability to interact with opiate receptors in vitro,9 which indicates potential analgesic activity.
• Alkaloids from California poppy enhanced gamma-aminobutyric acid (GABA) binding to rat brain synaptic membrane receptors. This finding may indicate a benzodiazepine-like activity.10 Constituents of California poppy exhibited dose-dependent binding to benzodiazepine receptors and displaced the benzodiazepine flurazepam from the receptor.11
• A sedative effect was observed for California poppy extract after injection in experimental models in terms of both behavioral effects and promotion of sleep.12,13 At lower doses, an anxiolytic effect was observed.12 Sedative effects have also been observed after treatment with high oral doses.14 The sedative and anxiolytic effects of California poppy are most likely linked to benzodiazepine-receptor activation because they were antagonized by the benzodiazepine-receptor antagonist flumazenil in vivo (by injection).15
• Muscle relaxant and analgesic activities have been reported in vivo,11 although no muscle relaxant activity was observed in vivo in a later study. Dose-dependent peripheral analgesic activity was demonstrated for California poppy in vivo (by injection), but central analgesic activity was not recorded.15
• California poppy tincture inhibited experimentally induced contractions of isolated smooth muscle.13
• Two alkaloids isolated from California poppy, chelerythrine and sanguinarine, exhibited affinity for vasopressin receptors and demonstrated competitive inhibition of vasopressin binding in vitro.16 Substances that have this activity have been used pharmacologicly as renal agents, vasoconstricting agents, and hemostatics.
|
Clinical Studies |
• Single administration of a California poppy extract (equivalent to 6.7 g of herb) to volunteers resulted in a quantitative electroencephalographic (EEG) recording that was distinguishable from that obtained from placebo. Results from the self-rating assessment of alertness, however, did not differ from placebo.17 An acute sedative effect was not demonstrated, but analysis after ongoing administration may demonstrate a sedative effect.
• In two controlled clinical trials, the combination of California poppy and Corydalis cava normalized disturbed sleeping behavior without evidence of carry-over effects or addiction. This preparation consisted of alcoholic extracts of California poppy (standardized for protopine) and Corydalis (standardized for bulbocapnine) in the ratio of 4:1. The dosage was not defined.14
|
1 Bartram T. Encyclopedia of herbal medicine, ed 1. Dorset, England: Grace Publishers, 1995.
2 Felter HW, Lloyd JU. King’s American dispensatory, ed 18. Portland: Eclectic Medical Publications, 1905. rev 3, reprinted 1983
3 Cheney RH. Quart J Crude Drugs. 1963;3:413-416.
4 Brinker FJ. Eclectic dispensatory of botanical therapeutics, vol 2 . Eclectic Medical Publications, Sandy, Oregon, 1995.
5 Davis GS. The pharmacology of the newer materia medica. Davis, Detroit, 1892. Bender GA. Pharm Hist. 1980;22(2):49-59.
6 Tome F, Colombo ML, Caldiroli L. Phytochem Anal. 1999;10:264-267.
7 Beck MA, Haberlein H. Phytochem. 1999;50(2):329-332.
8 Kleber E, et al. Arzneim Forsch. 1995;45(2):127-131.
9 Reimeier C, et al. Arzneim Forsch. 1995;45(2):132-136.
10 Kardos J, Blasko G, Simonyi M. Arzneim Forsch. 1986;36(6):939-940.
11 Rolland A. Doctoral thesis, University of Metz, France, 1988. Cited in Schafer HL et al. Arzneim Forsch. 1995;45(2):124-126.
12 Rolland A, et al. Planta Med. 1991;57(3):212-216.
13 Vincieri FF, et al. Pharmacol Res Commun. 1988;20(suppl 5):41-44.
14 Schafer HL, et al. Arzneim Forsch. 1995;45(2):124-126.
15 Rolland A, et al. Phytother Res. 2001;15:377-381.
16 Granger I, et al. Planta Med. 1992;58(1):35-38.
17 Schulz H, Jobert M, Hubner WD. Phytomed. 1998;5(6):449-458.
CASCARA
Other Common Name: | Cascara sagrada |
Botanical Names: | Rhamnus purshiana, Rhamnus purshianus,# Frangula purshiana# |
Family: | Rhamnaceae |
Plant Part Used: | Bark |
PRESCRIBING INFORMATION
Actions | Laxative | |
Potential Indications |
Based on appropriate evaluation of the patient, practitioners should consider prescribing cascara in formulations in the context of:
• Dyspepsia,* stimulating gastric secretion, loss of appetite, asthenia, postprandial bloating, coated tongue, itching of skin, in combination with gentian, rhubarb, and boldo (3)
|
* Cascara has also been used in traditional herbal medicine for treating constipation and dyspepsia and is recommended by both the Commission E and ESCOP for the short-term treatment of constipation. (4,5)
** This dose range is extrapolated from the British Pharmaceutical Codex 1934, the British Pharmacopoeia 1932, and the author’s education and experience.
SUPPORTING INFORMATION
1 British Herbal Medicine Association. British herbal compendium. Bournemouth: BHMA, 1992.
2 Blumenthal M, et al, editors. The complete German Commission E monographs: therapeutic guide to herbal medicines. Austin: American Botanical Council, 1998.
3 van Gorkom BA, et al. Aliment Pharmacol Ther. 1999;13(4):443-452.
4 Scientific Committee of the European Scientific Cooperative on Phytotherapy [ESCOP]. ESCOP monographs: Rhamni purshiani cortex. Argyle House, Gandy Street, Exeter, Devon, EX4 3LS, United Kingdom: European Scientific Cooperative on Phytotherapy, ESCOP Secretariat, June 1997.
5 de Smet PAGM, et al, editors. Adverse effects of herbal drugs. Berlin: Springer-Verlag, 1993.
6 Cummings JH, et al. Br Med J. 1974;1:537-541.
7 Nusko G, et al. Gut. 2000;46(5):651-655.
8 Mascolo N, et al. Phytother Res. 1998;12(supp 1):S143-S145.
9 Nadir A, Reddy D, Van Thiel DH. Am J Gastroenterol. 2000;95(12):3634-3637.
10 British Herbal Medicine Association’s Scientific Committee. British herbal pharmacopoeia. Bournemouth: BHMA, 1983.
11 Felter HW, Lloyd JU. King’s American dispensatory, ed 18. Portland: Eclectic Medical Publications, 1905. rev 3, reprinted 1983
12 Ellingwood F, Lloyd JU. American materia medicam, therapeutics and pharmacognosy, ed 11. Portland: Eclectic Medical Publications, 1983.
13 Vogel VJ. American Indian medicine. Norman, Okla: University of Oklahoma Press, 1970.
14 Wagner H, Bladt S. Plant drug analysis: a thin layer chromatography atlas, ed 2. Berlin: Springer-Verlag, 1996.
15 de Witte P, Lemli L. Hepatogastroenterol. 1990;37(6):601-605.
16 Geboes K. Verh K Acad Geneeskd Belg. 1995;57(1):51-74.
17 Izzo AA, Mascolo N, Capasso F. Dig Dis Sci. 1998;43(8):1605-1620.
18 Beynen AC. Artery. 1987;14(4):190-197.
CAT’S CLAW
Other Common Name: | Uña de gato |
Botanical Name: | Uncaria tomentosa |
Family: | Rubiaceae |
Plant Part Used: | Stem bark |
PRESCRIBING INFORMATION
Actions | Immune enhancing, antiinflammatory, antioxidant | |
Potential Indications |
* This dose range is extrapolated from traditional use of decoction of the bark.3
SUPPORTING INFORMATION
Traditional Prescribing | |
Pharmacologic Research |
Cat’s claw stem bark contains a number of oxindole alkaloids.7 Two different chemotypes of U. tomentosa that have been identified are likely to have distinctly different pharmacologic properties. One chemotype contains only, or predominantly, pentacyclic oxindole alkaloids (POA);the other contains POA and significant quantities of tetracyclic oxindole alkaloids (TOA). Intriguingly, indigenous priests are said to be able to identify the correct chemotype and harvest exclusively the chemotype containing POA, even though the two chemotypes are botanically identical.6,7
• Cat’s claw extract has exhibited antioxidant activity in vitro8 and antiinflammatory activity in experimental models after oral administration.9–11 Results of an in vitro study suggested that the antiinflammatory action may be a result of immunomodulation via suppression of tumor necrosis factor-alpha synthesis.12
• Cat’s claw extract has significantly stimulated interleukin-1 and interleukin-6 production in vitro.13 Cat’s claw extracts and POA stimulated phagocytosis in vitro and by injection.14–16 POA were found to induce endothelial cells to release a factor that influences the proliferation of lymphocytes.6,17 The TOA antagonized the effects of the POA.6 These studies indicate immune enhancement for the POA chemotypes.
|
Clinical Studies |
• A double-blind, randomized study assessed the effects of a freezedried aqueous extract of U. tomentosa on the mutagenic activity of urine collected from 12 smokers and 12 nonsmokers. A progressive decrease in mutagenic activity in the smokers’ urine was observed with increasing dose.20
• In an uncontrolled trial, 13 patients with HIV took 20 mg/day of an aqueous hydrochloric acid extract of U. tomentosa root (containing 12 mg total POA/g) for 2.2 to 5.0 months. Although the total white blood cell count remained unchanged within the group, results indicated that low values were raised and high values were lowered. The lymphocyte count increased significantly to an average of approximately 35%. However, no significant changes in T4/T8 cell ratios were observed.6
• Standardized U. tomentosa root extract was used in a long-term, open study involving 44 patients with AIDS.1 The daily dose varied from 20 to 60 mg per day (the dried herb equivalent would be much higher), with some patients also taking azidothymidine (AZT). Patients who had CD4 lymphocyte counts of 200 to 500 × 106/L demonstrated the best results for immunologic parameters:
|
1 Jones K. Cat’s claw: healing vine of Peru. Seattle: Sylvan Press, 1995.
2 Bourdy G, et al. J Ethnopharmacol. 2000;70(2):87.
3 Obregón Vilches, Lida E. Cat’s claw: Uncaria genus. Botanical, chemical, and pharmacological studies of Uncaria tomentosa and Uncaria guianensis. Lima: Instituto de Fitoterapia Americano, 1995.
4 Hilepo JN, Bellucci AG, Mossey RT. Nephron. 1997;77(3):361.
5 Maxwell N. Witch doctor’s apprentice, ed 3. New York: Citadel Press, 1990.
6 Keplinger K, et al. J Ethnopharmacol. 1999;64:23.
7 Laus G, Brossner D, Keplinger K. Phytochemistry. 1997;45(4):855.
8 Desmarchelier C, et al. Phytother Res. 1997;11(3):254.
9 Sandoval M, et al. Ailment Pharmacol Ther. 1998;12(12):1279-1289.
10 Miller MJS, et al. Peditr Res. 1999;45:114A.
11 Aquino R, et al. J Nat Prod. 1991;54(2):453-459.
12 Sandoval M, et al. Free Radic Biol Med. 2000;29(1):71-78.
13 LeMaire I, et al. J Ethnopharmacol. 1999;64(2):109-115.
14 Wagner H, et al. Planta Med. 1985;51(2):139.
15 Wagner H, Kreutzkamp B, Jurcic K. Planta Med. 1985;51(5):419.
16 United States Patent 5302611, April 12, 1994.
17 Wurm M, et al. Planta Med. 1998;64(8):701-704.
18 Stuppner H, et al. Planta Med. 1993;59(Suppl):A583.
19 Salazar EL, Jayme V. Proc West Pharmacol Soc. 1998;41:123-124.
CELERY SEED
Botanical Name: | Apium graveolens |
Family: | Umbelliferae |
Plant Part Used: | Fruit (sometimes referred to as seed) |
PRESCRIBING INFORMATION
Actions | Diuretic, antiinflammatory, antirheumatic | |
Potential Indications |
* This dose range is extrapolated from the British Pharmaceutical Codex 1934, the British Herbal Pharmacopoeia 1983, the British Herbal Compendium 1992, and the author’s education and experience.
SUPPORTING INFORMATION
Traditional Prescribing | |
The Eclectics considered celery seed as a nervine tonic.4 | |
Pharmacologic Research |
Apium graveolens seeds contain an essential oil consisting of terpenes and phthalides (especially 3-n-butyl phthalide).1
• Oral celery seed oil significantly elevated glutathione S-transferase activity in vivo compared with controls.6,7 Two groups of components within celery seed oil (limonene-type monoterpenes and butyl phthalides) appeared to be responsible for this activity. Further testing showed that the phthalide compounds were more active than the limonene-type monoterpenes.8
• Celery seed oil administered orally increased liver tissue regeneration.9
Buy Membership for Complementary Medicine Category to continue reading. Learn more here
|